These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1637564)

  • 21. The potential of the essential fatty acid-deficient hairless rat as a psoriasis screening model for topical anti-proliferative drugs.
    Jensen M; Groth L; Hølmer G; Hansen HS; Fullerton A
    Skin Pharmacol Appl Skin Physiol; 2002; 15(6):401-13. PubMed ID: 12476014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topical D-vitamins: multiparametric comparison of the irritant potential of calcipotriol, tacalcitol and calcitriol in a hairless guinea pig model.
    Fullerton A; Serup J
    Contact Dermatitis; 1997 Apr; 36(4):184-90. PubMed ID: 9165200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903).
    Kragballe K
    Arch Dermatol; 1989 Dec; 125(12):1647-52. PubMed ID: 2531570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Calcipotriol].
    Guilhou JJ
    Ann Dermatol Venereol; 2001 Mar; 128(3 Pt 1):229-37. PubMed ID: 11319386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topical calcipotriol (MC 903) for psoriasis: a clinical study.
    Mozzanica N; Cattaneo A; Schmitt E; Legori A; Finzi AF
    Acta Derm Venereol Suppl (Stockh); 1994; 186():169-70. PubMed ID: 8073826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the effects of calcipotriol, prednicarbate and clobetasol 17-propionate on normal skin assessed by ultrasound measurement of skin thickness.
    Lévy J; Gassmüller J; Schröder G; Audring H; Sönnichsen N
    Skin Pharmacol; 1994; 7(4):231-6. PubMed ID: 8024805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The importance of accurate dosage of topical agents: a method of estimating involved area and application to calcipotriol treatment failures.
    Osborne JE; Hutchinson PE
    J Eur Acad Dermatol Venereol; 2002 Jul; 16(4):367-73. PubMed ID: 12224694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New treatment of psoriasis with the vitamin D analogue calcipotriol].
    Austad J
    Tidsskr Nor Laegeforen; 1993 Nov; 113(29):3580-1. PubMed ID: 8273098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Zinc finger protein A20 is involved in the antipsoriatic effect of calcipotriol.
    Liu X; Liu Y; Xu M; Li J; Teng X; Cheng H; Xia Y
    Br J Dermatol; 2016 Aug; 175(2):314-24. PubMed ID: 26875609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A double-blind, randomized quantitative comparison of calcitriol ointment and calcipotriol ointment on epidermal cell populations, proliferation and differentiation.
    Körver JE; Vissers WH; van Rens DW; Pasch MC; van Erp PE; Boezeman JB; van De Kerkhof PC
    Br J Dermatol; 2007 Jan; 156(1):130-7. PubMed ID: 17199579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two cases of contact dermatitis caused by calcipotriol cream.
    Garcia-Bravo B; Camacho F
    Am J Contact Dermat; 1996 Jun; 7(2):118-9. PubMed ID: 8796754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of psoriasis with calcipotriol used as monotherapy.
    Ramsay CA
    J Am Acad Dermatol; 1997 Sep; 37(3 Pt 2):S53-4. PubMed ID: 9344185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative study of calcipotriol and anthralin for chronic plaque psoriasis in a day care treatment center.
    Dutz JP; Lui H
    Int J Dermatol; 1998 Jan; 37(1):51-3. PubMed ID: 9522242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pilot study to assess the safety and efficacy of topical calcipotriol treatment in childhood psoriasis.
    Park SB; Suh DH; Youn JI
    Pediatr Dermatol; 1999; 16(4):321-5. PubMed ID: 10469423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcipotriol ointment versus cream in psoriasis vulgaris.
    Duweb G; Aldebani S; Elzorghany A; Benghazil M; Alhaddar J
    Int J Clin Pharmacol Res; 2003; 23(2-3):47-51. PubMed ID: 15018018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Occlusion enhances the efficacy of topical calcipotriol in the treatment of psoriasis vulgaris.
    Bourke JF; Berth-Jones J; Hutchinson PE
    Clin Exp Dermatol; 1993 Nov; 18(6):504-6. PubMed ID: 8252786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxicity of 1,25-dihydroxyvitamin D3, tacalcitol, and calcipotriol after topical treatment in rats.
    Mortensen JT; Lichtenberg J; Binderup L
    J Investig Dermatol Symp Proc; 1996 Apr; 1(1):60-3. PubMed ID: 9627694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcipotriol vs. tazarotene as combination therapy with narrowband ultraviolet B (311 nm): efficacy in patients with severe psoriasis.
    Schiener R; Behrens-Williams SC; Pillekamp H; Kaskel P; Peter RU; Kerscher M
    Br J Dermatol; 2000 Dec; 143(6):1275-8. PubMed ID: 11122033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topical vitamin D3 derivatives impair the epidermal permeability barrier in normal mouse skin.
    von Brenken S; Jensen JM; Fartasch M; Proksch E
    Dermatology; 1997; 194(2):151-6. PubMed ID: 9094464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proactive treatment with calcipotriol reduces recurrence of plaque psoriasis.
    Ito K; Koga M; Shibayama Y; Tatematsu S; Nakayama J; Imafuku S
    J Dermatol; 2016 Apr; 43(4):402-5. PubMed ID: 26434738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.